Actively Recruiting
Efficacy and Biomarker Development for Lung Cancer Treated With Immune Checkpoint Inhibitors
Led by Hunan Province Tumor Hospital · Updated on 2024-08-02
12000
Participants Needed
1
Research Sites
310 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of the study is to find some biomarkers to predict the the adverse events of Immune Checkpoint Inhibitors monotherapy or plus platinum based chemotherapy in lung cancer.
CONDITIONS
Official Title
Efficacy and Biomarker Development for Lung Cancer Treated With Immune Checkpoint Inhibitors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Understand the trial and provide signed, dated informed consent
- Are 18 years or older
- Have histologically or cytologically confirmed lung cancer
- Are treated with Immune Checkpoint Inhibitors with or without chemotherapy
- Predicted survival of 12 weeks or more
- Adequate bone marrow and organ function
- Have measurable lesions according to RECIST 1.1
You will not qualify if you...
- Do not meet all inclusion criteria, including lacking data to evaluate adverse events
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Hunan Cancer Hospital
Changsha, Hunan, China, 410013
Actively Recruiting
Research Team
Y
Yongchang Zhang, MD
CONTACT
N
Nong Yang, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here